Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
At baseline assessment, acute TSCI patients had higher mean serum phosphate (1.51 ± 0.16 mmol/L vs 1.19 ± 0.12 mmol/L, p < 0.001) although corrected calcium, 25OHD3, PTH and ALP concentrations did not differ.
Source: Baseline Musculoskeletal Parameters in Both Cohorts. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Open-label reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a prospective open-label non-randomised study investigating early administration of intravenous ZOL after acute TSCI and longitudinal effects on BMD and bone turnover outcomes.
Source: Methods.
The ‘acute interventional cohort’ included patients aged ≥ 18 years who sustained acute TSCI ≤ 12 weeks prior to recruitment and were admitted to Royal North Shore Hospital or Royal Rehab, Sydney (tertiary SCI referral centres) between November 2018 and June 2022.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Preventing OsteoPorosis in Spinal Cord Injury (POPSCI) Study: Early Zoledronic Acid Infusion in Patients with Acute Spinal Cord Injury
Study design awaiting verification · Calcified Tissue International · 2024
Original publication title
Preventing OsteoPorosis in Spinal Cord Injury (POPSCI) Study: Early Zoledronic Acid Infusion in Patients with Acute Spinal Cord Injury
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Accelerated sub-lesional bone loss is common in the first 2 to 3 years after traumatic spinal cord injury (TSCI), particularly in the distal femur and proximal tibia. Few studies have explored efficacy of antiresorptives for acute bone loss prevention post-TSCI, with limited data for knee bone mineral density (BMD) or beyond two years follow-up. An open-label non-randomized study was performed at Royal North Shore Hospital and Royal Rehab Centre, Sydney between 2018 and 2023. An ‘acute interventional cohort’ (n = 11) with TSCI (duration ≤ 12-weeks) received a single infusion of 4 mg zoledronic acid (ZOL) at baseline.
A ‘chronic non-interventional cohort’ (n = 9) with TSCI (duration 1 to 5-years) did not receive ZOL. All participants underwent baseline and 6-monthly blood tests (including CTx and P1NP) and 12-monthly DXA BMD scans (including distal femur and proximal tibia). Participants were predominantly Caucasian and male (mean age 38.4 years). At baseline, the ‘acute’ cohort had higher serum CTx, P1NP and sclerostin concentrations, while the ‘chronic’ cohort had lower left hip and knee BMD. Majority with acute TSCI experienced an acute phase reaction after ZOL (9/11; 82%).
In the acute cohort, left hip BMD fell by mean ~ 15% by 48 months. Left distal femoral and proximal tibial BMD declined by mean ~ 6 to 13% at 12 months and ~ 20 to 23% at 48 months, with a tendency towards greater BMD loss in motor-complete TSCI. A single early ZOL infusion in acute TSCI could not attenuate rapidly declining hip and knee BMD. Prospective controlled studies are required to establish the optimal strategy for preventing early bone loss after acute TSCI.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-024-01292-3.
Authors’ abstract
Accelerated sub-lesional bone loss is common in the first 2 to 3 years after traumatic spinal cord injury (TSCI), particularly in the distal femur and proximal tibia. Few studies have explored efficacy of antiresorptives for acute bone loss prevention post-TSCI, with limited data for knee bone mineral density (BMD) or beyond two years follow-up. An open-label non-randomized study was performed at Royal North Shore Hospital and Royal Rehab Centre, Sydney between 2018 and 2023. An ‘acute interventional cohort’ (n = 11) with TSCI (duration ≤ 12-weeks) received a single infusion of 4 mg zoledronic acid (ZOL) at baseline.
A ‘chronic non-interventional cohort’ (n = 9) with TSCI (duration 1 to 5-years) did not receive ZOL. All participants underwent baseline and 6-monthly blood tests (including CTx and P1NP) and 12-monthly DXA BMD scans (including distal femur and proximal tibia). Participants were predominantly Caucasian and male (mean age 38.4 years). At baseline, the ‘acute’ cohort had higher serum CTx, P1NP and sclerostin concentrations, while the ‘chronic’ cohort had lower left hip and knee BMD. Majority with acute TSCI experienced an acute phase reaction after ZOL (9/11; 82%).
In the acute cohort, left hip BMD fell by mean ~ 15% by 48 months. Left distal femoral and proximal tibial BMD declined by mean ~ 6 to 13% at 12 months and ~ 20 to 23% at 48 months, with a tendency towards greater BMD loss in motor-complete TSCI. A single early ZOL infusion in acute TSCI could not attenuate rapidly declining hip and knee BMD. Prospective controlled studies are required to establish the optimal strategy for preventing early bone loss after acute TSCI.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00223-024-01292-3.
Publication and source details
Original title: Preventing OsteoPorosis in Spinal Cord Injury (POPSCI) Study: Early Zoledronic Acid Infusion in Patients with Acute Spinal Cord Injury
Shejil Kumar; Jean Doyle; Cameron Wood; Roxana Heriseanu; Gerard Weber; Lianne Nier; James W. Middleton; Lyn March; Roderick J. Clifton-Bligh; Christian M. Girgis
Calcified Tissue International · 2024
© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100001232Royal Australasian College of Physicianshttp://dx.doi.org/10.13039/501100001774University of Sydneyhttp://dx.doi.org/10.13039/100012633Royal North Shore HospitalUniversity of SydneyOpen Access funding enabled and organized by CAUL and its Member Institutions
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T09:20:05.136258+00:00
DOI: 10.1007/s00223-024-01292-3 · PMC11531416